This report contains genetic and antigenic characterization data generated at the Worldwide Influenza Centre for viruses with collection dates after 31 August 2023 until 31 January 2024.
The 2022–2023 ECDC PPS was the third EU-wide point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals.
This is a summary of the fourth joint inter-agency report on integrated analysis of antimicrobial consumption and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals in the European Union (JIACRA IV – 2019–2021).
This report provides an integrated analysis of relationships between antimicrobial consumption in humans and food- producing animals and the occurrence of antimicrobial resistance in bacteria from humans and food- producing animals, respectively.
The main aim of the genomic study described in this surveillance report was to determine the distribution of the highly drug-resistant clade of Klebsiella pneumoniae (sequence type (ST) 39 in Greek hospitals in 2022.
This report describes and summarises the results of the 2022 external quality assessment (EQA) of antimicrobial susceptibility testing (AST) by clinical laboratories that participate in the European Antimicrobial Resistance Surveillance Network (EARS-Net).
In 2022, for the first time, all European Union/European Economic Area (EU/EEA) countries reported data to the European Antimicrobial Resistance Surveillance Network (EARS-Net).
For 2022, 29 countries (27 European Union (EU) Member States and two European Economic Area (EEA) countries – Iceland and Norway) reported data on antimicrobial consumption.
This executive summary showcases results derived from 2022 antimicrobial resistance (AMR) data, sourced from invasive isolates reported to both the Central Asian and European Surveillance of Antimicrobial Resistance (CAESAR) network and the European Antimicrobial Resistance Surveillance Network (EARS-Net).